06/30/22 4:30 PMNasdaq : NYXH low floatInformation on the total number of voting rights and sharesREGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 30, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH)RHEA-AIneutral
06/07/22 4:30 PMNasdaq : NYXH low floatNyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index Mont-Saint-Guibert, Belgium – June 7, 2022 4:30pm ET / 10:30pm CET– Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development andRHEA-AIvery positive
06/01/22 4:30 PMNasdaq : NYXH fda approvallow floatFDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study New smartphone application, upgraded activation chip, improved user interface, and stimulation amplitude trimming enhance patient experience and comfort Mont-Saint-Guibert, Belgium – June 1, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SARHEA-AIvery positive
05/10/22 2:55 AMNasdaq : NYXH low floatNyxoah Reports First Quarter 2022 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports First Quarter 2022 Financial and Operating Results Mont-Saint-Guibert, Belgium – May 10, 2022, 08:50pm CET / 2:50pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development andRHEA-AIneutral
05/09/22 4:30 PMNasdaq : NYXH low floatNyxoah Reports First Quarter 2022 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports First Quarter 2022 Financial and Operating Results Mont-Saint-Guibert, Belgium – May 9, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development andRHEA-AIneutral
05/06/22 1:00 AMNasdaq : NYXH conferenceslow floatInvitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 8, 2022REGULATED INFORMATION May 6, 2022, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “ Company ”) Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 8, 2022RHEA-AIpositive
05/06/22 1:00 AMNasdaq : NYXH managementlow floatNyxoah Nominates Raymond Cohen and Virginia Kirby for Appointment to Its Board of DirectorsNyxoah Nominates Raymond Cohen and Virginia Kirby for Appointment to Its Board of Directors Mont-Saint-Guibert, Belgium – May 6, 2022, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development andRHEA-AIneutral
04/28/22 4:30 PMNasdaq : NYXH earningslow floatNyxoah to Release First Quarter 2022 Financial Results on May 9 and Host Conference Call on May 10, 2022Nyxoah to Release First Quarter 2022 Financial Results on May 9 and Host Conference Call on May 10, 2022 Mont-Saint-Guibert, Belgium – April 28, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on theRHEA-AIneutral
03/24/22 4:30 PMNasdaq : NYXH earningslow floatNyxoah Reports Full Year 2021 Operating and Financial ResultsREGULATED INFORMATION Nyxoah Reports Full Year 2021 Operating and Financial Results Mont-Saint-Guibert, Belgium – March 24, 2022, 9:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development andRHEA-AIneutral
03/14/22 6:30 PMNasdaq : NYXH low floatBETTER SLEEP Achieves Primary Endpoint Across All Patient CohortsBETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts First clinical data demonstrating effectiveness of HGNS to treat CCC patients As previously disclosed, confirms achievement of primary endpoint of AHI4 reductions for entire population, CCC cohort, and non-CCC cohort at six months,RHEA-AIvery positive